Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...
6h
The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and $11 billion for Medicaid over a decade. Total Medicare drug spending over ...
The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...
6h
The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback